How does Thymosin Alpha-1 (Tα1) work?
28-amino-acid peptide derived from prothymosin alpha. Activates Toll-like receptors (both TLR2 and TLR9) on dendritic cells, broadly enhancing T-cell-mediated immune responses without direct antigen specificity. In plain terms, Thymosin Alpha-1 (Tα1) is immune-system peptide. Approved in many countries for hepatitis B/C and as adjunct to chemotherapy. Used here for chronic immune issues and post-illness recovery. Mechanistic detail like this comes largely from preclinical and early research, the human picture is limited.
What people use it for
- Users with chronic immune issues
- Post-illness recovery support
- Cancer / hepatitis-adjunct context under medical care
References
- Thymosin alpha 1 in chronic hepatitis B and C — Sherman KE et al., Gut, 2003
- The efficacy and safety of thymosin alpha1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial — Wu J et al., BMJ, 2025
- The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial — Wu J et al., Critical Care, 2013
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Thymosin Alpha-1 (Tα1)
Last updated 2026-06-06.